Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Sen Wei is active.

Publication


Featured researches published by Sen Wei.


PLOS ONE | 2013

Clinical Significance of EML4-ALK Fusion Gene and Association with EGFR and KRAS Gene Mutations in 208 Chinese Patients with Non-Small Cell Lung Cancer

Ying Li; Yongwen Li; Tong Yang; Sen Wei; Jing Wang; Min Wang; Yuli Wang; Qinghua Zhou; Hongyu Liu; Jun Chen

The EML4-ALK fusion gene has been recently identified in a small subset of non-small cell lung cancer (NSCLC) patients who respond positively to ALK inhibitors. The characteristics of the EML4-ALK fusion gene in Chinese patients with NSCLC are poorly understood. Here, we report on the prevalence of EML4-ALK, EGFR status and KRAS mutations in 208 Chinese patients with NSCLC. EGFR mutations were found in 24.5% (51/208) of patients. In concordance with previous reports, these mutations were identified at high frequencies in females (47.5% vs 15.0% in males; P<0.05); never-smokers (42.3% vs 13.9% in smokers; P<0.05), and adenocarcinoma patients (44.2% vs 8.0% in non-adenocarcinoma patients; P<0.05). There were only 2.88% (6/208) patients with KRAS mutations in our study group. We identified 7 patients who harbored the EML4-ALK fusion gene (3.37%, 7/208), including 4 cases with variant 3 (57.1%), 2 with variant 1, and 1 with variant 2. All positive cases corresponded to female patients (11.5%, 7/61). Six of the positive cases were non-smokers (7.69%, 6/78). The incidence of EML4-ALK translocation in female, non-smoking adenocarcinoma patients was as high as 15.2% (5/33). No EGFR/KRAS mutations were detected among the EML4-ALK positive patients. Pathological analysis showed no difference between solid signet-ring cell pattern (4/7) and mucinous cribriform pattern (3/7) in ALK-positive patients. Immunostaining showed intratumor heterogeneity of ALK rearrangement in primary carcinomas and 50% (3/6) of metastatic tumors with ALK-negative staining. Meta-analysis demonstrated that EML4-ALK translocation occurred in 4.84% (125/2580) of unselected patients with NSCLC, and was also predominant in non-smoking patients with adenocarcinoma. Taken together, EML4-ALK translocations were infrequent in the entire NSCLC patient population, but were frequent in the NSCLC subgroup of female, non-smoker, adenocarcinoma patients. There was intratumor heterogeneity of ALK rearrangement in primary carcinomas and at metastatic sites.


Cancer Letters | 2016

Circulating tumor DNA identified by targeted sequencing in advanced-stage non-small cell lung cancer patients

Song Xu; Feng Lou; Yi Wu; Da-Qiang Sun; Jingbo Zhang; Wei Chen; Hua Ye; Jinghao Liu; Sen Wei; Mingyu Zhao; Wen-Jun Wu; Xue-Xia Su; Rong Shi; Lindsey Jones; Xue F. Huang; Si-Yi Chen; Jun Chen

Non-small cell lung cancers (NSCLC) have unique mutation patterns, and some of these mutations may be used to predict prognosis or guide patient treatment. Mutation profiling before and during treatment often requires repeated tumor biopsies, which is not always possible. Recently, cell-free, circulating tumor DNA (ctDNA) isolated from blood plasma has been shown to contain genetic mutations representative of those found in the primary tumor tissue DNA (tDNA), and these samples can readily be obtained using non-invasive techniques. However, there are still no standardized methods to identify mutations in ctDNA. In the current study, we used a targeted sequencing approach with a semi-conductor based next-generation sequencing (NGS) platform to identify gene mutations in matched tDNA and ctDNA samples from 42 advanced-stage NSCLC patients from China. We identified driver mutations in matched tDNA and ctDNA in EGFR, KRAS, PIK3CA, and TP53, with an overall concordance of 76%. In conclusion, targeted sequencing of plasma ctDNA may be a feasible option for clinical monitoring of NSCLC in the near future.


Acta Pharmacologica Sinica | 2010

Application of RT-PCR in formalin-fixed and paraffin-embedded lung cancer tissues.

Fan Zhang; Zhuomin Wang; Hongyu Liu; Yun Bai; Sen Wei; Ying Li; Min Wang; Jun Chen; Qinghua Zhou

AbstractAim:To analyze gene expression in formalin-fixed, paraffin-embedded lung cancer tissues using modified method.Methods:Total RNA from frozen tissues was extracted using TRIZOL reagent. RNA was extracted from formalin-fixed, paraffin-embedded tissues by digestion with proteinase K before the acid-phenol:chloroform extraction and carrier precipitation. We modified this method by using a higher concentration of proteinase K and a longer digestion time, optimized to 16 hours. RT-PCR and real-time RT-PCR were used to check reproducibility and the concordance between frozen and paraffin-embedded samples.Results:The results showed that the RNA extracted from the paraffin-embedded lung tissues had high quality with the most fragment length between 28S and 18S bands (about 1000 to 2000 bases). The housekeeping gene GUSB exhibited low variation of expression in frozen and paraffin-embedded lung tissues, whereas PGK1 had the lowest variation in lymphoma tissues. Furthermore, real-time PCR analysis of the expression of known prognostic genes in non-small cell lung carcinoma (NSCLC) demonstrated an extremely high correlation (r>0.880) between the paired frozen and formalin-fixed, paraffin-embedded specimens.Conclusion:This improved method of RNA extraction is suitable for real-time quantitative RT-PCR, and may be used for global gene expression profiling of paraffin-embedded tissues.


Tumor Biology | 2012

Effects of BTG2 on proliferation inhibition and anti-invasion in human lung cancer cells

Sen Wei; Chunfang Hao; Xin Li; Honglin Zhao; Jun Chen; Qinghua Zhou

The objective of the study was to investigate the impact of the B cell translocation gene 2 (BTG2) on lung cancer cell growth, proliferation, metastasis, and other biological characteristics and to provide experimental evidence for the biological treatment of human lung cancer. A pcDNA3.1-BTG2 eukaryotic expression vector was constructed and transfected into the human lung cancer cell line A549. The biological changes in the BTG2-expressing cells were analyzed using growth curves, the MTT (tetrazolium) assay, propidium iodide (PI) staining, and the Transwell invasion chamber. Additionally, Western blotting was used to determine the impact of BTG2 on the protein expression of cyclin D1, MMP-1, and MMP-2. Compared to the empty vector-transfected A549 cells or the mock-transfected A549 cells, the pcDNA3.1-BTG2-transfected A549 cells grew significantly slower. No significant differences were detected between the empty vector-transfected group and the mock-transfected A549 cells. The growth curve analysis and the PI staining showed that the pcDNA3.1-BTG2-transfected cells grew significantly slower than the empty vector-transfected A549 cells (P < 0.05). The cell invasion assay results suggested that the invasion rate of the pcDNA3.1-BTG2-transfected A549 cells was significantly slower than the invasion rate of the empty vector-transfected group and the mock-transfected group (P < 0.05). The overexpression of BTG2 may inhibit the protein expression of cyclin D1, MMP-1, and MMP-2 in A549 cells. The overexpression of BTG2 may inhibit the growth, proliferation, and invasiveness of the A549 human lung cancer cell line.


The Annals of Thoracic Surgery | 2011

Thymoma With Pure Red Cell Aplasia and Good's Syndrome

Jun Chen; Yongbo Yang; Daxing Zhu; Gang Chen; Sen Wei; Xiaoming Qiu; Qinghua Zhou

Thymoma patients with pure red cell aplasia (PRCA) or hypogammaglobulinemia (Goods syndrome) are rare, whereas those with both PRCA and Goods syndrome are even rarer. Here we present the case report of a 70-year-old woman with invasive thymoma and simultaneous PRCA and Goods syndrome, who achieved complete PRCA remission after thymectomy.


Acta Pharmacologica Sinica | 2009

Different BAG-1 isoforms have distinct functions in modulating chemotherapeutic-induced apoptosis in breast cancer cells

Hongyu Liu; Zhuomin Wang; Yun Bai; Min Wang; Ying Li; Sen Wei; Qinghua Zhou; Jun Chen

AbstractAim:BAG-1 is a multifunctional anti-apoptotic gene with four isoforms, and different BAG-1 isoforms have different anti-apoptotic functions. In this study, we transfected BAG-1 isoforms into the human breast cancer cell lines Hs578T (ER negative) and MCF-7 (ER positive) to study their effect on apoptosis with or without estrogens.Methods:The constructed recombinant expression vectors carrying individual BAG-1 isoforms was used to transfect human breast cancer cell lines Hs578T (ER negative) and MCF-7 (ER positive). After stable cell lines were made, a variety of apoptosis-inducing agents, including doxorubicin, docetaxel, and 5-FU, was used to treat these cell lines with or without estrogen to test the role of BAG-1. The mechanism by which BAG-1 affected the function of Bcl-2 was exploredby using the cycloheximide chase assay.Results:The BAG-1 p50 and p46 isoforms significantly enhanced the resistance to apoptosis in both cell lines according to flow cytometry analysis. BAG-1 p33 and p29 failed to protect the transfected cells from apoptosis. The cell viability assay showed that only BAG-1 p50, but not p46, p33, or p29, increased estrogen-dependent function in ER-positive cell line MCF-7. Only BAG-1 p50 dramatically increased its anti-apoptotic ability in the presence of estrogen, while estrogen has very little effect on the anti-apoptotic ability of other BAG-1 isoforms. In the detection of the expression of K-ras, Hsp70, cytochrome c, Raf-1, ER-α, and Bcl-2 in MCF-7 cells by Western blot, only Bcl-2 protein expression was significantly increased in MCF-7 cells transfected with BAG-1 p50 and p46, respectively. Furthermore, the cycloheximide chase assay indicated that the degradation of Bcl-2 protein was extended in the BAG-1 p50 and p46 transfected MCF-7 cells.Conclusion:Distinct isoforms of BAG-1 have different anti-apoptotic functions in breast cancer cells, and that the BAG-1 p50 isoform can potentiate the role of estrogen in ER-positive breast cancer.


Surgery Today | 2009

Mediastinal solitary fibrous tumor with right diaphragm invasion: Report of a case

Xingyang Xue; Jun Chen; Wei Ma; Daxing Zhu; Weiguo Zhang; Gang Chen; Sen Wei; Qinghua Zhou

Mediastinal solitary fibrous tumors (SFTs) are rarely found in adults and there are few reports describing primary mediastinal SFT invading the diaphragm. We report the case of a 47-year-old woman with a large right inferior mediastinal SFT. Magnetic resonance imaging showed the tumor invading the right lower lobe of the lung and the right hemidiaphragm, with displacement of the inferior vena cava (IVC) and right lobe of the liver. Angiogram showed IVC stenosis. To our knowledge, this is the first report of complete resection of the tumor combined with right lower lobectomy of the lung and partial resection and reconstruction of the right diaphragm with a Dacron flap.


World Journal of Surgical Oncology | 2011

Primary Leiomyoma of the pleura.

Xiaoming Qiu; Daxin Zhu; Sen Wei; Gang Chen; Jun Chen; Qinghua Zhou

Primary leiomyoma of the pleura is extremely rare. A 45-year-old man presented with a complaint of right chest pain. Chest computed tomography demonstrated a solid, round pleural mass in the right anterior chest wall. The mass was completely resected, and histopathological examination revealed a localized primary pleural leiomyoma. The patient was followed and has been disease-free for over 15 months. This is the first report of primary leiomyoma of the pleura in China. A review of the literature on primary leiomyoma of the pleura is presented.


World Journal of Surgical Oncology | 2012

Primary lung lymphoma involving the superior vena cava

Sen Wei; Xin Li; Xiaomin Qiu; Honglin Zhao; Gang Chen; Jun Chen; Qinghua Zhou

Primary lung lymphoma (PLL) presenting as a primary pulmonary lesion is rare and usually affects elderly people. Here we describe a 25-year-old Chinese man diagnosed with primary lung lymphoma, which presented as a huge lung tumor mimicking a primary lung cancer and involving the superior vena cava. He underwent double-sleeve reconstructions of bronchus and pulmonary arteries with right upper- and middle-lobe lobectomy along with replacement of the superior vena cava with a graft, and was then given standard chemotherapy of CHOP plus Rituximab. The patient has been well, showing no local recurrence or distal metastasis during a 27-month follow-up.


Thoracic Cancer | 2012

Survival and bronchial carcinoid tumors: Development of surgical techniques in a 30‐year experience of 82 patients in China

Sen Wei; Chunfang Hao; Lei Gong; Chengguang Hu; Jianhong Lian; Qinghua Zhou

Background:  We aimed to identify the factors determining long‐term survival after surgical management for bronchial typical carcinoid (TC) and atypical carcinoids (AC) and to compare the clinical outcome of the different surgical strategies used in the two periods of 1980–1994 and 1995–2005.

Collaboration


Dive into the Sen Wei's collaboration.

Top Co-Authors

Avatar

Jun Chen

Tianjin Medical University General Hospital

View shared research outputs
Top Co-Authors

Avatar

Qinghua Zhou

Tianjin Medical University General Hospital

View shared research outputs
Top Co-Authors

Avatar

Gang Chen

Tianjin Medical University General Hospital

View shared research outputs
Top Co-Authors

Avatar

Song Xu

Tianjin Medical University General Hospital

View shared research outputs
Top Co-Authors

Avatar

Xin Li

Tianjin Medical University General Hospital

View shared research outputs
Top Co-Authors

Avatar

Jinghao Liu

Tianjin Medical University General Hospital

View shared research outputs
Top Co-Authors

Avatar

Daxing Zhu

Tianjin Medical University General Hospital

View shared research outputs
Top Co-Authors

Avatar

Hongyu Liu

Tianjin Medical University General Hospital

View shared research outputs
Top Co-Authors

Avatar

Xiaoming Qiu

Tianjin Medical University General Hospital

View shared research outputs
Top Co-Authors

Avatar

Zuoqing Song

Tianjin Medical University General Hospital

View shared research outputs
Researchain Logo
Decentralizing Knowledge